Isabelle Amigues1, Cesare Russo2,3, Jon T Giles1, Aylin Tugcu2,4, Richard Weinberg2,5, Sabahat Bokhari2,5, Joan M Bathon1. 1. Division of Rheumatology (I.A., J.T.G., J.M.B.), Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. 2. Division of Cardiology (C.R., A.T., R.W., S.B.), Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. 3. Current address for Cesare Russo: Novartis Institutes for BioMedical Research, Basel, Switzerland. 4. Current address for Aylin Tugcu: Bristol Myers Squibb, Lawrenceville, NJ. 5. Nuclear Cardiology Laboratory (R.W., S.B.), Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital.
Abstract
BACKGROUND: The goal of this study was to assess the prevalence of myocardial microvascular dysfunction in rheumatoid arthritis (RA) patients without clinical cardiovascular disease and its association with RA characteristics and measures of cardiac structure and function. METHODS: Participants with RA underwent rest and vasodilator stress N-13 ammonia positron emission tomography and echocardiography. Global myocardial blood flow was quantified at rest and during peak hyperemia. Myocardial flow reserve (MFR) was calculated as peak stress myocardial blood flow/rest myocardial blood flow. A small number of asymptomatic and symptomatic non-RA controls were also evaluated. RESULTS: In RA patients, mean±SD MFR was 2.9±0.8, with 29% having reduced MFR (<2.5). Male sex and higher interleukin-6 were significantly associated with lower MFR, while the use of tumor necrosis factor inhibitors was associated with higher MFR. Lower MFR was associated with higher left ventricle mass index and higher left ventricle volumes but not with ejection fraction or diastolic dysfunction. RA and symptomatic controls had comparable MFR (mean±SD: 2.9±0.8 versus 2.55±0.6; P=0.48). In contrast, MFR was higher in the asymptomatic controls (mean±SD: 3.25±0.7) although not statistically different. CONCLUSIONS: Reduced MFR was observed in a third of RA patients without clinical cardiovascular disease and was associated with a measure of inflammation and with higher left ventricle mass and volumes. MFR in RA patients was similar to controls referred for clinical scans (symptomatic controls). Whether reduced MFR contributes to the increased risk for heart failure in RA remains unknown.
BACKGROUND: The goal of this study was to assess the prevalence of myocardial microvascular dysfunction in rheumatoid arthritis (RA) patients without clinical cardiovascular disease and its association with RA characteristics and measures of cardiac structure and function. METHODS:Participants with RA underwent rest and vasodilator stress N-13 ammonia positron emission tomography and echocardiography. Global myocardial blood flow was quantified at rest and during peak hyperemia. Myocardial flow reserve (MFR) was calculated as peak stress myocardial blood flow/rest myocardial blood flow. A small number of asymptomatic and symptomatic non-RA controls were also evaluated. RESULTS: In RApatients, mean±SD MFR was 2.9±0.8, with 29% having reduced MFR (<2.5). Male sex and higher interleukin-6 were significantly associated with lower MFR, while the use of tumor necrosis factor inhibitors was associated with higher MFR. Lower MFR was associated with higher left ventricle mass index and higher left ventricle volumes but not with ejection fraction or diastolic dysfunction. RA and symptomatic controls had comparable MFR (mean±SD: 2.9±0.8 versus 2.55±0.6; P=0.48). In contrast, MFR was higher in the asymptomatic controls (mean±SD: 3.25±0.7) although not statistically different. CONCLUSIONS: Reduced MFR was observed in a third of RApatients without clinical cardiovascular disease and was associated with a measure of inflammation and with higher left ventricle mass and volumes. MFR in RApatients was similar to controls referred for clinical scans (symptomatic controls). Whether reduced MFR contributes to the increased risk for heart failure in RA remains unknown.
Authors: Robert J Mentz; Jacob P Kelly; Thomas G von Lueder; Adriaan A Voors; Carolyn S P Lam; Martin R Cowie; Keld Kjeldsen; Ewa A Jankowska; Dan Atar; Javed Butler; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor Journal: J Am Coll Cardiol Date: 2014-11-24 Impact factor: 24.094
Authors: Deepankar Datta; William R Ferrell; Roger D Sturrock; Sachin T Jadhav; Naveed Sattar Journal: Atherosclerosis Date: 2006-06-23 Impact factor: 5.162
Authors: David Hürlimann; Adrian Forster; Georg Noll; Frank Enseleit; Rémy Chenevard; Oliver Distler; Markus Béchir; Lukas E Spieker; Michel Neidhart; Beat A Michel; Renate E Gay; Thomas F Lüscher; Steffen Gay; Frank Ruschitzka Journal: Circulation Date: 2002-10-22 Impact factor: 29.690
Authors: John M Davis; Véronique L Roger; Cynthia S Crowson; Hilal Maradit Kremers; Terry M Therneau; Sherine E Gabriel Journal: Arthritis Rheum Date: 2008-09
Authors: Emily S Lau; Samantha M Paniagua; James Sawalla Guseh; Vijeta Bhambhani; Markella V Zanni; Paul Courchesne; Asya Lyass; Martin G Larson; Daniel Levy; Jennifer E Ho Journal: J Am Coll Cardiol Date: 2019-09-24 Impact factor: 24.094
Authors: Brittany N Weber; Emma Stevens; Lourdes M Perez-Chada; Jenifer M Brown; Sanjay Divakaran; Camden Bay; Courtney Bibbo; Jon Hainer; Sharmila Dorbala; Ron Blankstein; Viviany R Taqueti; Joseph F Merola; Elena Massarotti; Karen Costenbader; Katherine Liao; Marcelo F Di Carli Journal: JACC Cardiovasc Imaging Date: 2021-03-17
Authors: Ashley S Manchanda; Alan C Kwan; Mariko Ishimori; Louise E J Thomson; Debiao Li; Daniel S Berman; C Noel Bairey Merz; Caroline Jefferies; Janet Wei Journal: Front Cardiovasc Med Date: 2022-04-15
Authors: Elisabetta Zanatta; Claudia Colombo; Gianpiero D'Amico; Thomas d'Humières; Carlo Dal Lin; Francesco Tona Journal: Int J Mol Sci Date: 2019-11-07 Impact factor: 5.923